Chapel Hill, NC – According to filings with the U.S. Securities and Exchange Commission, Altis Biosystems is raising $2,196,595.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Biron played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Altis Biosystems

Altis’s mission is to develop, manufacture and sell innovative services and research tools to accelerate drug development. These tools will allow scientists and pharmaceutical companies to more quickly and accurately have access to the medicines they need, at a much lower cost. Altis Biosystems is a biotechnology company, based in Chapel Hill, North Carolina. Altis has developed patent-pending stem cell technology that recreates the human intestinal epithelium. Our organ on a chip products produce a layer of human or animal intestinal stem and differentiated cells, either of the small or large intestine. These cells can be used for disease modeling, precision medicine, microbiome research, and compound screening. The primary users of our product would be pharmaceutical companies and CROs.

To learn more about Altis Biosystems, visit http://altisbiosystems.com/

Contact:
Michael Biron, Chief Executive Officer
516-255-7290
mike@altisbiosystems.com
https://www.linkedin.com/in/michaelbiron/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved